摘要
目的:探讨卡瑞利珠单抗治疗中晚期食管癌的临床效果及用药安全性。方法:将2020年1月—2023年12月陕健医韩城矿务局总医院收治的80例中晚期食管癌患者随机分为对照组(常规化疗方案)和观察组(在对照组基础上加用卡瑞利珠单抗),每组40例。对比两组治疗效果、血清肿瘤标志物指标[癌胚抗原(CEA)与癌相关糖蛋白抗原(CA153)]、血清可溶性E-钙黏蛋白(sE-Cad)、不良反应发生情况。结果:观察组客观缓解率高于对照组(P=0.038);治疗后,两组CA153、CEA、sE-Cad水平均下降,且观察组低于对照组(P<0.05);两组不良反应发生率对比,无统计学差异(P>0.05)。结论:卡瑞利珠单抗治疗中晚期食管癌的效果较好且用药安全性较高,可以显著降低患者肿瘤标志物水平,下调血清中sE-Cad的表达水平。
Objective:To investigate the clinical effect and drug safety of camrelizumab in the treatment of middle and advanced esophageal cancer.Methods:Eighty cases of middle and advanced esophageal cancer patients admitted to the Shanxi Health Medical Hancheng Mining Bureau General Hospital from January 2020 to December 2023 were randomly divided into control group(conventional chemotherapy regimen)and observation group(with camrelizumab on the basis of the control group),with 40 cases in each group.Compare the treatment effect,serum tumor marker indexes[carcinoembryonic antigen(CEA)and cancer-associated glycoprotein antigen(CA153)],serum soluble E-calcium mucin(sE-Cad),and the occurrence of adverse reactions between the two groups.Results:The objective remission rate of the observation group was higher than that of the control group(P=0.038);after treatment,the levels of CA153,CEA,and sE-Cad decreased in both groups,and the observation group was lower than that of the control group(P<0.05);the difference in the incidence of adverse reactions between the two groups was statistically insignificant when compared with the incidence of adverse reactions in the two groups(P>0.05).Conclusion:Camrelizumab is effective and safe for the treatment of middle and advanced esophageal cancer,which can significantly reduce the level of tumor markers and down-regulate the expression level of sE-Cad in serum.
作者
徐艳妮
刘荣荣
Xu Yanni;Liu Rongrong(Department of Pharmacy,Shanxi Health Medical Hancheng Mining Bureau General Hospital,Hancheng 715400,Shaanxi Province,China;Department of Medical Oncology,Xingping People's Hospital,Xingping 713100,Shaanxi Province,China)
出处
《中外医药研究》
2024年第27期39-41,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
作者简介
通信作者:刘荣荣。
